Literature DB >> 241513

Fabry disease: diagnosis by alpha-galactosidase activities in tears.

D L Johnson, M A Del Monte, E Cotlier, R J Desnick.   

Abstract

The enzymatic diagnosis of hemizygotes with Fabry disease and heterozygous carriers was accomplished by the fluorometric determination of alpha-galactosidase activities in tears. Two components of total alpha-galactosidase activity were differentiated by their relative thermostabilities and by chromatography on DEAE-cellulose. The major component, alpha-galactosidase A, was thermolabile and represented approximately 90% of total activity; the remaining activity was thermostable, eluted at a slightly higher salt concentration and was designated alpha-galactosidase B. A single, symmetric pH optimum was observed for total alpha-galactosidase activities from heterozygotes and normal individuals, whereas the total activity from hemizgotes, which was about 10% of that in normal controls, had a broad pH profile, identical to those for alpha-galactosidase B activities from all individuals studied. The apparent Km values for total activities were 3.2, 4.0, and greater than 13 mM for normal individuals, heterozygotes, and hemizygotes, respectively. In contrast, apparent Km values for alpha-galactosidase B activities were greater than 13 mM for all individuals, further suggesteng that the residual activity in hemizygotes with Fabry disease represented the alpha-galactosidase B component. of the potential inhibitors studied, alpha-D-melibiose was found to competitively inhibit total alpha-galactosidase activity (Ki approximately 10 mM). These studies demonstrate that tears provide an easily obtainable source of freshly secreted enzyme for the diagnosis of hemizygotes and heterozygotes with Fabry disease and suggest that tears may be useful for the diagnosis of other inborn errors of metabolism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241513     DOI: 10.1016/0009-8981(75)90382-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.

Authors:  R J Desnick; K J Dean; G Grabowski; D F Bishop; C C Sweeley
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

2.  Ultrastructure of muscle and sensory nerve in Fabry's disease.

Authors:  F M Tomé; M Fardeau; G Lenoir
Journal:  Acta Neuropathol       Date:  1977-06-15       Impact factor: 17.088

3.  The 4-methylumbelliferone sulphate sulphatases of human tears.

Authors:  T W Jordan; F Heiss; B Monk; J Nicholls
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

4.  Biochemical phenotyping of a single sibship with both cystinosis and Fabry disease.

Authors:  W A Gahl; M Adamson; I Kaiser-Kupfer; I H Ludwig; H J O'Connell; W Cohen; J Barranger
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

5.  Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.

Authors:  H S Bernstein; D F Bishop; K H Astrin; R Kornreich; C M Eng; H Sakuraba; R J Desnick
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.